{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:16:45Z","timestamp":1794705405152,"version":"4.9.1"},"reference-count":57,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,8,21]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Curative-intent multimodality treatment\u2014combining local treatments such as surgery or radiotherapy with systemic therapy\u2014is the cornerstone of care in stage II\u2013III non-small cell lung cancer (NSCLC). Since 2017, the systemic therapy backbones with multimodality treatment have undergone a dramatic transformation, driven by a series of pivotal, practice-changing clinical trials. Immunotherapy and targeted therapies, previously confined to the advanced\/metastatic setting, are now firmly embedded in curative-intent regimens. Maintenance immunotherapy following chemoradiation in unresectable stage III disease, adjuvant tyrosine kinase inhibitors in resected epidermal growth factor receptor\/anaplastic lymphoma kinase-positive tumours, neoadjuvant and perioperative chemoimmunotherapy in resectable stage II\/III NSCLC and adjuvant chemoimmunotherapy following resection have all become new standards of care.<\/jats:p>\n                  <jats:p>This state-of-the-art review synthesises the key evidence underpinning these developments, highlights their clinical implications and identifies challenges to implementation\u2014particularly the need for redefined clinical pathways, accurate pretreatment staging, timely biomarker testing and coordinated multidisciplinary decision-making. A novel treatment algorithm is proposed to support clinicians in navigating these complex treatment choices.<\/jats:p>\n                  <jats:p>We conclude that immunotherapy and targeted agents have irrevocably altered curative-intent NSCLC care, establishing multiple new standards that sometimes overlap and compete. In the surgical multimodality treatment pathway, neoadjuvant and perioperative chemoimmunotherapy offers the opportunity to increase the uptake of systemic therapy in comparison to adjuvant therapy and is considered by these authors to represent the optimal treatment path for most patients.<\/jats:p>\n                  <jats:p>In this unprecedented era of therapeutic expansion, the greatest challenge is no longer the absence of effective treatments, but the complexity of selecting, sequencing and delivering them, as well as patient optimisation. Lung cancer services must evolve through proactive pathway redesign, integrated diagnostics and new models of multidisciplinary care. High-quality, biomarker-driven and patient-centred care is now achievable for many patients with stage II\u2013III NSCLC\u2014but it will require system-level adaptation to deliver it.<\/jats:p>","DOI":"10.1136\/thorax-2025-223096","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:34:01Z","timestamp":1757093641000},"page":"707-717","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017\u20132025"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-5253","authenticated-orcid":false,"given":"Matthew","family":"Evison","sequence":"first","affiliation":[{"name":"Lung Cancer and Thoracic Surgery Directorate, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Manchester Academic Health Science Centre (MAHSC), Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenali","family":"Chitnis","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Netto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cove-Smith","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz","family":"Shah","sequence":"additional","affiliation":[{"name":"Kent Oncology Centre, Maidstone, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Steele","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Walls","sequence":"additional","affiliation":[{"name":"Queen\u2019s University Belfast, Belfast, UK"},{"name":"Belfast Health & Social Care Trust, Belfast, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"West","sequence":"additional","affiliation":[{"name":"Thoracic Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6412-7516","authenticated-orcid":false,"given":"Neal","family":"Navani","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"2026061502201439000_81.7.707.1","unstructured":"Lam F , et al . Global cancer observatory: cancer today. International Agency for Research on Cancer; 2020. Available: http:\/\/gco.iarc.fr\/today"},{"key":"2026061502201439000_81.7.707.2","unstructured":"Toy E , ANderson A , Hugh M . Lung cancer girft programme national specialty report. NHS England & NHS Improvement; 2021."},{"key":"2026061502201439000_81.7.707.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026061502201439000_81.7.707.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2026061502201439000_81.7.707.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"2026061502201439000_81.7.707.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"2026061502201439000_81.7.707.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"2026061502201439000_81.7.707.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"2026061502201439000_81.7.707.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2026061502201439000_81.7.707.10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308"},{"key":"2026061502201439000_81.7.707.11","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026061502201439000_81.7.707.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.003"},{"key":"2026061502201439000_81.7.707.13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/JTO.0000000000000551","article-title":"Non\u2013Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy","volume":"10","author":"Carbone","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026061502201439000_81.7.707.14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann Oncol"},{"key":"2026061502201439000_81.7.707.15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj117"},{"key":"2026061502201439000_81.7.707.16","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(20)30091-X","article-title":"Stage III non-small cell lung cancer: a UK national survey of practice","volume":"139","author":"Evison","year":"2020","journal-title":"Lung Cancer (Auckl)"},{"key":"2026061502201439000_81.7.707.17","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jtho.2023.09.044","article-title":"OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer","volume":"18","author":"Houda","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026061502201439000_81.7.707.18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026061502201439000_81.7.707.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.02.009"},{"key":"2026061502201439000_81.7.707.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614"},{"key":"2026061502201439000_81.7.707.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100160","article-title":"Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer?","volume":"6","author":"Walls","year":"2024","journal-title":"J Liq Biopsy"},{"key":"2026061502201439000_81.7.707.22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.9.673"},{"key":"2026061502201439000_81.7.707.23","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00299-2022","article-title":"What is the optimal management of potentially resectable stage III-N2 NSCLC? Results of a fixed-effects network meta-analysis and economic modelling","volume":"9","author":"Evison","year":"2023","journal-title":"ERJ Open Res"},{"key":"2026061502201439000_81.7.707.24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"The Lancet"},{"key":"2026061502201439000_81.7.707.25","unstructured":"NICE . Lung cancer: diagnosis and management NICE guideline. NICE Clinical Guideline; 2019."},{"key":"2026061502201439000_81.7.707.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"2026061502201439000_81.7.707.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594"},{"key":"2026061502201439000_81.7.707.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30729-5"},{"key":"2026061502201439000_81.7.707.29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.18.00131","article-title":"SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor\u2013Mutant Non\u2013Small-Cell Lung Cancer","volume":"37","author":"Pennell","year":"2019","journal-title":"JCO"},{"key":"2026061502201439000_81.7.707.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.8918"},{"key":"2026061502201439000_81.7.707.31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cllc.2023.02.002","article-title":"Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2","volume":"24","author":"Tsutani","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2026061502201439000_81.7.707.32","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol"},{"key":"2026061502201439000_81.7.707.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532"},{"key":"2026061502201439000_81.7.707.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"2026061502201439000_81.7.707.35","unstructured":"Vallieres E , et al . IMpower010: overall survival interim analysis of a phase iii study of atezolizumab vs vest supportive care in resected NSCLC. World Conference on Lung Cancer Vienna, Austria; 2022."},{"key":"2026061502201439000_81.7.707.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.001"},{"key":"2026061502201439000_81.7.707.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00518-6"},{"key":"2026061502201439000_81.7.707.38","doi-asserted-by":"crossref","first-page":"S971","DOI":"10.1016\/j.annonc.2022.07.1056","article-title":"930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS\/KEYNOTE-091","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"2026061502201439000_81.7.707.39","unstructured":"Excellence NIfHaC . Atezolizumab for adjuvant treatment of resected non-small cell lung cancer. NICE; 2022. Available: www.nice.org.uk\/guidance\/ta823"},{"key":"2026061502201439000_81.7.707.40","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","author":"NM-aC","year":"2014","journal-title":"The Lancet"},{"key":"2026061502201439000_81.7.707.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"2026061502201439000_81.7.707.42","doi-asserted-by":"crossref","unstructured":"Jonathan Spicer NG , Provencio M , Wang C , et al . J clin oncol. Neoadjuvant Nivolumab (NIVO) + Chemotherapy (Chemo) vs Chemo in Patients (Pts) with Resectable NSCLC: 4-Year Update from CheckMate 816. 2024 ASCO Annual Meeting; Chicago, USA, 2024 doi:10.1200\/JCO.2024.42.17_suppl.LBA8010","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010"},{"key":"2026061502201439000_81.7.707.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02660-6"},{"key":"2026061502201439000_81.7.707.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01224-2"},{"key":"2026061502201439000_81.7.707.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875"},{"key":"2026061502201439000_81.7.707.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302983"},{"key":"2026061502201439000_81.7.707.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926"},{"key":"2026061502201439000_81.7.707.48","doi-asserted-by":"crossref","first-page":"S1297","DOI":"10.1016\/j.annonc.2023.10.052","article-title":"LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)","volume":"34","author":"Spicer","year":"2023","journal-title":"Ann Oncol"},{"key":"2026061502201439000_81.7.707.49","unstructured":"NHS England . Achieving world-class cancer outcomes: a strategy for England 2015-2020. Progress report 2016-17. National cancer transformation programme 2018; publications gateway reference 07318."},{"key":"2026061502201439000_81.7.707.50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/resp.14549","article-title":"Proposed quality indicators and recommended standard reporting items in performance of EBUS bronchoscopy: An official World Association for Bronchology and Interventional Pulmonology Expert Panel consensus statement","volume":"28","author":"Steinfort","year":"2023","journal-title":"Respirology"},{"key":"2026061502201439000_81.7.707.51","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2016.253","article-title":"How should performance in EBUS mediastinal staging in lung cancer be measured?","volume":"115","author":"Evison","year":"2016","journal-title":"Br J Cancer"},{"key":"2026061502201439000_81.7.707.52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747"},{"key":"2026061502201439000_81.7.707.53","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-208890"},{"key":"2026061502201439000_81.7.707.54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cllc.2020.05.007","article-title":"Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma","volume":"21","author":"Anand","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2026061502201439000_81.7.707.55","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1200\/JOP.2016.014019","article-title":"Impact of Reflex EGFR\/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"13","author":"Cheema","year":"2017","journal-title":"J Oncol Pract"},{"key":"2026061502201439000_81.7.707.56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.6204"},{"key":"2026061502201439000_81.7.707.57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.09.014","article-title":"PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816","volume":"19","author":"Forde","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:21:13Z","timestamp":1781515273000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,15]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/thorax-2025-223096"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223096","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}